Vifor Pharma AG-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013296)
◆英語タイトル:Vifor Pharma AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013296
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:50
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Vifor Pharma AG (Vifor Pharma), a subsidiary of Galenica Ltd is a healthcare service provider that discovers, develops, manufactures, and commercializes prescription and over the counter pharmaceutical products for the treatment of iron replacement therapy. The company offers products for treatment of iron deficiency, a range of non prescription products for the treatment of infectious diseases, and iron based phosphate binder for controlling serum phosphorus levels in patients with chronic kidney disease undergoing dialysis. Vifor Pharma’s clinical programs concentrates on safety and efficacy of Broncho Vaxom for respiratory tract infections in children and in chronic obstructive pulmonary disease in adults; and uro vaxom for recurrent urinary tract infections. It has manufacturing facilities in Switzerland, the UK and Portugal. Vifor Pharma is headquartered in Glattbrugg, Switzerland.

Vifor Pharma AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vifor Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Vifor Pharma AG, Medical Devices Deals, 2011 to YTD 2017 10
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Relypsa Secures USD2.6 Million in Venture Funding 13
Relypsa Raises US$80 Million In Series C Financing 14
Relypsa Secures USD62.4 Million in Venture Funding 16
Partnerships 17
Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 17
Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 18
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 19
Probi Enters Into Co-Marketing Agreement With Vifor Pharma 20
Licensing Agreements 21
Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 21
Vifor Pharma Expands Licensing Agreement with ChemoCentryx 22
Vifor Pharma Expands Licensing Agreement with ChemoCentryx for CCX168 23
Vifor Pharma Expands Licensing Agreement with Roche 24
Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 25
Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 26
Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 27
Isotechnika Pharma Enters Into Licensing Agreement With Vifor Pharma For voclosporin 29
Hikma Pharma Enters Into Licensing Agreement With Vifor Pharma For Ferinject 30
Equity Offering 31
Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 31
Relypsa Raises USD172 Million in Public Offering of Shares 32
Relypsa Completes Public Offering Of Shares For US$101.2 Million 34
Relypsa Completes IPO For US$86.7 Million 36
Acquisition 38
Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 38
Relypsa May Sell Itself 40
Galenica Acquires Remaining Stake In Vifor Uriach Pharma From Grupo Uriach 41
Vifor Pharma AG – Key Competitors 42
Vifor Pharma AG – Key Employees 43
Vifor Pharma AG – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 46
Financial Announcements 46
Aug 08, 2017: Vifor Pharma Reports Strong H1 2017 Results And Raises Guidance 46
Corporate Communications 47
Oct 06, 2016: Galenica: New Management at Vifor Pharma and new Galenica Group CFO designated 47
May 10, 2016: Vifor Pharma appoints Colin Bond as Chief Financial Officer 48
Government and Public Interest 49
Feb 20, 2017: Vifor Pharma and ECCO Announces One-Year Research Grant for Iron Deficiency 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Vifor Pharma AG, Pharmaceuticals & Healthcare, Key Facts 2
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vifor Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vifor Pharma AG, Deals By Therapy Area, 2011 to YTD 2017 9
Vifor Pharma AG, Medical Devices Deals, 2011 to YTD 2017 10
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Relypsa Secures USD2.6 Million in Venture Funding 13
Relypsa Raises US$80 Million In Series C Financing 14
Relypsa Secures USD62.4 Million in Venture Funding 16
Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 17
Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 18
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 19
Probi Enters Into Co-Marketing Agreement With Vifor Pharma 20
Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 21
Vifor Pharma Expands Licensing Agreement with ChemoCentryx 22
Vifor Pharma Expands Licensing Agreement with ChemoCentryx for CCX168 23
Vifor Pharma Expands Licensing Agreement with Roche 24
Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 25
Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 26
Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 27
Isotechnika Pharma Enters Into Licensing Agreement With Vifor Pharma For voclosporin 29
Hikma Pharma Enters Into Licensing Agreement With Vifor Pharma For Ferinject 30
Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 31
Relypsa Raises USD172 Million in Public Offering of Shares 32
Relypsa Completes Public Offering Of Shares For US$101.2 Million 34
Relypsa Completes IPO For US$86.7 Million 36
Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 38
Relypsa May Sell Itself 40
Galenica Acquires Remaining Stake In Vifor Uriach Pharma From Grupo Uriach 41
Vifor Pharma AG, Key Competitors 42
Vifor Pharma AG, Key Employees 43
Vifor Pharma AG, Other Locations 44
Vifor Pharma AG, Subsidiaries 44

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Vifor Pharma AG-製薬・医療分野:企業M&A・提携分析(Vifor Pharma AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆